UHRF2 enhances autophagy and oncogenic traits in hepatocellular carcinoma (HCC) by interacting with PRDX1 and PARP1, suggesting its potential as a biomarker and therapeutic target for HCC. Here, PRDX1 is linked to hepatocellular carcinoma.